Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease

Antioxidants and Redox Signaling

Volumn 16, Issue 9, 2012, Pages 855-868

  Thomas, Bobby ^a   Banerjee, Rebecca ^a   Starkova, Natalia N ^a   Zhang, Steven F ^a   Calingasan, Noel Y ^a   Yang, Lichuan ^a   Wille, Elizabeth ^a   Lorenzo, Beverly J ^a   Ho, Daniel J ^a   Beal, M Flint ^a   Starkov, Anatoly ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOPHILIN D; FREE RADICAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MITOCHONDRION; BREATHING RATE; CELL ISOLATION; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATION CONTROL; RESPIRATORY CHAIN; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; ASTROCYTES; BASAL GANGLIA; CALCIUM; CELL DEATH; CYCLOPHILINS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HUMANS; MICE; MICE, KNOCKOUT; MICROGLIA; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MPTP POISONING; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 84863229879     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3849     Document Type: Article

References (59)

1. Adam-Vizi V and Starkov AA. Calcium and mitochondrial reactive oxygen species generation: How to read the facts. J Alzheimers Dis 20: S413-426, 2010.
2. Adams JD, Klaidman LK, and Cadenas E. MPP+ redox cycling: A new mechanism involving hydride transfer. Ann NY Acad Sci 648: 239-240, 1992.
3. Andreyev AY, Kushnareva YE, and Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 70: 200-214, 2005. (Pubitemid 40512329)
4. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, and Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658-662, 2005. (Pubitemid 40488559)
5. Banerjee R, Starkov AA, Beal MF, and Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792: 651-663, 2009.
6. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, and Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 280: 18558-18561, 2005. (Pubitemid 41379552)
7. Basso E, Petronilli V, Forte MA, and Bernardi P. Phosphate is essential for inhibition of the mitochondrial permeability transition pore by cyclosporin A and by cyclophilin D ablation. J Biol Chem 283: 26307-26311, 2008.
8. Bernardi P. Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol Rev 79: 1127-1155, 1999. (Pubitemid 29473313)
9. Bredesen DE, Rao RV, and Mehlen P. Cell death in the nervous system. Nature 443: 796-802, 2006. (Pubitemid 44622684)
10. Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, and Dubinsky JM. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci 23: 4858-4867, 2003. (Pubitemid 36793212)
11. Chinopoulos C, Konrad C, Kiss G, Metelkin E, Torocsik B, Zhang SF, and Starkov AA. Modulation of F(0) F(1)-ATP synthase activity by cyclophilin D regulates matrix adenine nucleotide levels. FEBS J 278: 1112-1125, 2011.
12. Chinopoulos C, Starkov AA, and Fiskum G. Cyclosporin Ainsensitive permeability transition in brain mitochondria: Inhibition by 2-aminoethoxydiphenyl borate. J Biol Chem 278: 27382-27389, 2003. (Pubitemid 36899919)
13. Cleren C, Starkov AA, Calingasan NY, Lorenzo BJ, Chen J, and Beal MF. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiol Dis 20: 701-708, 2005. (Pubitemid 41619346)
14. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, and Beal MF. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 104: 1613-1621, 2008. (Pubitemid 351316765)
15. Damiano M, Starkov AA, Petri S, Kipiani K, Kiaei M, Mattiazzi M, Flint Beal M, and Manfredi G. Neural mitochondrial Ca2 + capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem 96: 1349-1361, 2006.
16. Dauer W and Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 39: 889-909, 2003. (Pubitemid 37130207)
17. Dawson TM, Ko HS, and Dawson VL. Genetic animal models of Parkinson's disease. Neuron 66: 646-661, 2010.
18. Dehmer T, Lindenau J, Haid S, Dichgans J, and Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74: 2213-2216, 2000. (Pubitemid 30217680)
19. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, and Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14: 1097-1105, 2008.
20. Du H, Guo L, Zhang W, Rydzewska M, and Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging 32: 398-406, 2011.
21. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, and Molkentin JD. Cyclophilin D controls mitochondrial pore-dependent Ca(2 + ) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest 120: 3680-3687, 2010.
22. Endo S, Ishiguro S, and Tamai M. Possible mechanism for the decrease of mitochondrial aspartate aminotransferase activity in ischemic and hypoxic rat retinas. Biochim Biophys Acta 1450: 385-396, 1999. (Pubitemid 29295488)
23. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, and Sudhof TC. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102: 3413-3418, 2005. (Pubitemid 40328059)
24. Furuya T, Hayakawa H, Yamada M, Yoshimi K, Hisahara S, Miura M, Mizuno Y, and Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 24: 1865-1872, 2004. (Pubitemid 38292797)
25. Giorgio V, Bisetto E, Soriano ME, Dabbeni-Sala F, Basso E, Petronilli V, Forte MA, Bernardi P, and Lippe G. Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex. J Biol Chem 284: 33982-33988, 2009.
26. Huser J, Rechenmacher CE, and Blatter LA. Imaging the permeability pore transition in single mitochondria. Biophys J 74: 2129-2137, 1998. (Pubitemid 28157948)
27. Jackson-Lewis V, Jakowec M, Burke RE, and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257-269, 1995.
28. Jackson-Lewis V and Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2: 141-151, 2007. (Pubitemid 47044700)
29. Klaidman LK, Adams JD, Jr., Leung AC, Kim SS, and Cadenas E. Redox cycling of MPP+ : Evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med 15: 169-179, 1993. (Pubitemid 23218819)
30. Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, and Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem 88: 1352-1360, 2004. (Pubitemid 38366910)
31. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, and Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156: 50-61, 1999. (Pubitemid 29152982)
32. Leong SF, Lai JC, Lim L, and Clark JB. The activities of some energy-metabolising enzymes in nonsynaptic (free) and synaptic mitochondria derived from selected brain regions. J Neurochem 42: 1306-1312, 1984. (Pubitemid 14137613)
33. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403-1409, 1999.
34. Martin LJ, Gertz B, Pan Y, Price AC, Molkentin JD, and Chang Q. The mitochondrial permeability transition pore in motor neurons: Involvement in the pathobiology of ALS mice. Exp Neurol 218: 333-346, 2009.
35. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, and Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652-658, 2005. (Pubitemid 40488558)
36. Oo TF and Burke RE. Histochemical methods for the detection of apoptosis in the nervous system. Curr Protoc Neurosci Chapter 1: Unit 1 15, 2007.
37. Perier C, Bove J, Wu DC, Dehay B, Choi DK, Jackson-Lewis V, Rathke-Hartlieb S, Bouillet P, Strasser A, Schulz JB, Przedborski S, and Vila M. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci USA 104: 8161-8166, 2007. (Pubitemid 47185892)
38. Petronilli V, Penzo D, Scorrano L, Bernardi P, and Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 276: 12030-12034, 2001.
39. Przedborski S and Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 13: 35-38, 1998.
40. Przedborski S, Tieu K, Perier C, and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36: 375-379, 2004. (Pubitemid 39619844)
41. Przedborski S and Vila M. The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 991: 189-198, 2003. (Pubitemid 36793814)
42. Reynolds AD, Banerjee R, Liu J, Gendelman HE, and Mosley RL. Neuroprotective activities of CD4+ CD25 + regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 82: 1083-1094, 2007. (Pubitemid 350133504)
43. Rose IA and O'Connell EL. Mechanism of aconitase action. I. The hydrogen transfer reaction. J Biol Chem242: 1870-1879, 1967.
44. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, and Korsmeyer SJ. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 102: 12005-12010, 2005. (Pubitemid 41291119)
45. Shepherd D and Garland PB. Methods Enzymol 13: 11-16, 1969.
46. Sims NR. Rapid isolation of metabolically active mitochondria from rat brain and subregions using Percoll density gradient centrifugation. J Neurochem 55: 698-707, 1990. (Pubitemid 120021648)
47. Starkov AA. Measurement of mitochondrial ROS production. Methods Mol Biol 648: 245-255, 2010.
48. Starkov AA, Polster BM, and Fiskum G. Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax. J Neurochem 83: 220-228, 2002.
49. Surmeier DJ, Guzman JN, and Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium 47: 175-182, 2010.
50. Suzuki K, Mizuno Y, Yamauchi Y, Nagatsu T, and Mitsuo Y. Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4- tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain. J Neurol Sci 109: 219-223, 1992.
51. Tanveer A, Virji S, Andreeva L, Totty NF, Hsuan JJ, Ward JM, and Crompton M. Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca2 + and oxidant stress. Eur J Biochem 238: 166-172, 1996.
52. Tatton NA and Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77: 1037-1048, 1997.
53. Thomas B. Parkinson's disease: From molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 11: 2077-2082, 2009.
54. Thomas B, von Coelln R, Mandir AS, Trinkaus DB, Farah MH, Leong Lim K, Calingasan NY, Flint Beal M, Dawson VL, and Dawson TM. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 26: 312-322, 2007. (Pubitemid 46561335)
55. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771, 2002. (Pubitemid 35386294)
56. Yamashima T. Ca2 +-dependent proteases in ischemic neuronal death: A conserved 'calpain-cathepsin cascade' from nematodes to primates. Cell Calcium 36: 285-293, 2004. (Pubitemid 38992354)
57. Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT,Williams C, Royce D, Risingsong R,Musiek ES, Morrow JD, Sporn M, and Beal MF. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer ofNrf2-mediated transcription. PLoS One 4: e5757, 2009.
58. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, Nathan C, and Ding A. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 207: 117-128, 2010.
59. Zoratti M and Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1241: 139-176, 1995.